Story

Praxis Stock Surges After Positive FDA Updates on Two Neurological Drugs

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Praxis Stock Surges After Positive FDA Updates on Two Neurological Drugs
Text size
Background

Shares of Praxis Precision Medicines (PRAX) surged more than 9% in pre-market trading Tuesday following a corporate update that significantly de-risked the regulatory pathways for two of its leading drug candidates. The company announced positive mid-cycle reviews from the U.S. Food and Drug Administration for both programs, coupled with a strong financial position that alleviates near-term funding concerns.

Key Regulatory Milestones

The FDA completed its mid-cycle reviews for both ulixacaltamide, a treatment candidate for essential tremor, and relutrigine, a therapy for rare developmental and epileptic encephalopathies. According to the company, regulators found no major safety or efficacy concerns for either program and opted not to convene an advisory committee, a development investors view as a positive signal ahead of final decisions.

The PDUFA target action date for relutrigine is December 27, 2026, and the date for ulixacaltamide is January 29, 2027.

Adding to the positive regulatory news, Praxis reported that FDA Bioresearch Monitoring inspections related to both drug applications were completed with zero Form FDA 483 observations. A clean inspection without any findings is a strong indicator of sound data integrity and smooth regulatory execution.

Financial Strength and Pipeline Progress

Sample IUX Markets – In-articleAd

Praxis also strengthened investor confidence by reporting a robust balance sheet. The company held approximately $1.4 billion in cash and investments as of June 30, 2026.

This cash position provides a financial runway into 2028, removing the risk of a near-term capital raise as the company awaits the FDA's approval decisions. Separately, Praxis disclosed it had received a third Breakthrough Therapy Designation for another pipeline asset, elsunersen, following positive trial results.

Market Reaction

The stock's 9.3% pre-market jump was a direct reaction to the company-specific news, standing in contrast to the broader market, where the Nasdaq Composite was slightly lower and the S&P 500 was flat. The move pushed Praxis shares toward the upper end of their 52-week range, reflecting strong investor optimism about the company's late-stage assets.

Read next

More on Stocks
Back to latest news

LATEST